Drug Safety

, Volume 37, Issue 4, pp 269–282

Thromboembolic Events in Women Exposed to Hormonal Contraception or Cyproterone Acetate in 2012: A Cross-Sectional Observational Study in 30 French Public Hospitals

  • Mathilde Gourbil
  • Aurélie Grandvuillemin
  • Marie-Noëlle Beyens
  • Nathalie Massy
  • Valérie Gras
  • Andréa D’Amico
  • Ghada Miremont-Salamé
  • Nadine Petitpain
  • The French Network of Regional Pharmacovigilance Centres
Original Research Article

DOI: 10.1007/s40264-014-0149-8

Cite this article as:
Gourbil, M., Grandvuillemin, A., Beyens, MN. et al. Drug Saf (2014) 37: 269. doi:10.1007/s40264-014-0149-8
  • 383 Downloads

Abstract

Background

In the context of the European reassessment of the benefit–risk balance of hormonal contraceptives, French data about thromboembolic events were requested.

Objective

The aim of this study was to determine the number of patients exposed to hormonal contraception or cyproterone acetate among hospitalized females diagnosed with a thromboembolic event in 2012, to retrospectively analyze specific risk factors of venous and arterial thromboembolism and to assess the magnitude of the under-reporting of such events to the national pharmacovigilance system.

Methods

This cross-sectional study included 15- to 49-year-old women with pulmonary embolism, venous cerebral thrombosis, ischemic stroke, or myocardial infarction, hospitalized in 2012, and identified within the computerized hospital databases of 30 French teaching hospitals.

Results

Among the 2,966 cases identified, 803 (27.1 %) patients had been exposed to a hormonal contraceptive (747) or to cyproterone acetate (56). Among these, there were 452 venous thromboembolic events (VTEs) and 351 arterial thromboembolic events (ATEs). Age ≥40 years and personal thrombophilia diagnosed after the event were the main VTE risk factors, while current smoking and age ≥40 years were the main ATE risk factors. The mean number of associated risk factors was significantly lower for VTE than for ATE (1.1 vs 2.3). The proportion of cases with no risk factors was higher for third- and fourth-generation than for first- and second-generation combined oral contraceptives. Overall, the under-reporting rate was 92.5 % (95 % CI 70.0–97.3).

Conclusion

This study highlighted the need to strengthen the knowledge of patients and health professionals about thromboembolic risk factors at the first prescription and renewal of hormonal contraceptives.

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Mathilde Gourbil
    • 1
  • Aurélie Grandvuillemin
    • 2
  • Marie-Noëlle Beyens
    • 3
  • Nathalie Massy
    • 4
  • Valérie Gras
    • 5
  • Andréa D’Amico
    • 1
  • Ghada Miremont-Salamé
    • 6
  • Nadine Petitpain
    • 7
  • The French Network of Regional Pharmacovigilance Centres
  1. 1.Regional Pharmacovigilance CentreUniversity HospitalLyonFrance
  2. 2.Regional Pharmacovigilance CentreUniversity HospitalDijonFrance
  3. 3.Regional Pharmacovigilance CentreUniversity Hospital, Hôpital de BellevueSaint-ÉtienneFrance
  4. 4.Regional Pharmacovigilance CentreUniversity Hospital, Hôpital Charles NicolleRouenFrance
  5. 5.Regional Pharmacovigilance CentreUniversity Hospital SudAmiensFrance
  6. 6.Regional Pharmacovigilance CentreUniversity Hospital, Hôpital PellegrinBordeauxFrance
  7. 7.Regional Pharmacovigilance CentreUniversity Hospital of NancyNancyFrance